Lexaria Bioscience Ratios and Metrics

Market cap in millions USD. Fiscal year is September - August.

Millions USD. Fiscal year is Sep - Aug.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 3, 2026	Aug '25 Aug 31, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023	Aug '22 Aug 31, 2022	Aug '21 Aug 31, 2021
Market Cap	8	17	62	8	18	36
Market Cap Growth	-57.44%	-72.15%	627.59%	-51.77%	-50.55%	-
Enterprise Value	6.16	14.97	55.02	6.82	11.19	23.76
Last Close Price	4.61	0.88	3.91	1.05	2.96	6.22
PS Ratio	49.96	24.39	133.15	37.56	68.97	49.28
PB Ratio	2.05	5.76	7.69	2.79	2.22	2.69
P/TBV Ratio	23.63	5.91	6.44	2.69	2.34	2.12
EV/Sales Ratio	31.76	21.21	118.52	30.15	43.81	32.88
Debt / Equity Ratio	0.01	0.03	0.01	0.05	0.00	0.00
Net Debt / Equity Ratio	-0.74	-0.62	-0.80	-0.43	-0.77	-0.88
Net Debt / EBITDA Ratio	0.46	0.16	1.13	0.21	0.94	2.09
Net Debt / FCF Ratio	0.47	0.18	1.28	0.22	1.24	2.92
Asset Turnover	0.04	0.11	0.08	0.04	0.02	0.09
Inventory Turnover	-	-	-	1.64	2.11	2.39
Quick Ratio	9.56	1.56	6.10	6.21	32.79	78.90
Current Ratio	10.60	2.32	7.18	8.03	35.96	81.18
Return on Equity (ROE)	-113.64%	-232.15%	-112.36%	-130.18%	-71.35%	-53.57%
Return on Assets (ROA)	-142.32%	-182.18%	-96.27%	-119.69%	-62.74%	-70.67%
Return on Invested Capital (ROIC)	-1005.85%	-1195.63%	-440.68%	-452.15%	-451.56%	-415.86%
Return on Capital Employed (ROCE)	-171.44%	-227.38%	-108.71%	-124.98%	-63.79%	-72.37%
Buyback Yield / Dilution	-32.40%	-45.34%	-87.24%	-12.38%	-34.02%	-58.34%
Total Shareholder Return	-32.40%	-45.34%	-87.24%	-12.38%	-34.02%	-58.34%

SEC Filings: 10-K · 10-Q